ClinicalTrialsFinder

Relapsed or Refractory T-cell Lymphomas Clinical Trials in Hiroshima

1 recruitingHiroshima, Japan

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb85 enrolled40 locationsNCT06035497